Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
Anne Weiss, Franck Touret, Cécile Baronti, Magali Gilles, Bruno Hoen, Antoine Nougaırède, Xavier de Lamballerie, Morten Otto Alexander Sommer
Abstract
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.
Topics & Concepts
NiclosamidePotencySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BETA (programming language)PharmacologyVirologyCoronavirus disease 2019 (COVID-19)Alpha (finance)BiologyMedicineInternal medicineIn vitroBiochemistryNursingComputer scienceProgramming languagePatient satisfactionDiseaseInfectious disease (medical specialty)Construct validityEcologySARS-CoV-2 and COVID-19 ResearchRespiratory viral infections researchMosquito-borne diseases and control